Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated contest for the biotech firm. The deal, finalized after Novo Nordisk withdrew ...

Novo Nordisk’s CEO dared Pfizer to bid more if it wanted obesity drug developer Metsera so badly. So Pfizer did, with a $10 billion bid that edges out what the Danish pharmaceutical giant was willing ...

Pfizer is a Buy for medium- to long-term investors, trading at a low P/E and undervalued versus peers, with strong non-COVID growth. Strategic pivots include aggressive R&D, cost-cutting, and the ...

Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an ...

Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...